• diseases
  • M.B.P. is the inventor on patents covering SAP as a therapeutic target in amyloidosis and amyloid-associated diseases, and the use of CPHPC for SAP depletion, owned by Pentraxin Therapeutics Ltd, a University College London spinout company in which he and P.N.H. own shares. (pubmedcentralcanada.ca)
  • Clinical
  • The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present 1 . (pubmedcentralcanada.ca)
  • There is promise that two drugs, tafamidis and diflunisal, may improve the outlook, since they were demonstrated in randomized clinical trials to benefit patient affected by the related condition FAP-1 otherwise known as transthyretin-related hereditary amyloidosis. (wikipedia.org)
  • people
  • Nevertheless, because amyloid fibers can be detected in muscle in low amounts, it raises some concern about whether people could develop amyloidosis as a result of ingesting meat from an animal with the disease. (wikipedia.org)
  • development
  • This report provides information on the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease), complete with latest updates, and special features on late-stage and discontinued projects. (sbwire.com)
  • It also reviews key players involved in the therapeutic development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease). (sbwire.com)
  • A review of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. (sbwire.com)
  • Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease). (sbwire.com)
  • Thus, in a sense, SAA amyloidosis may be considered a contagious disease, although whether this occurs or is important in the development of naturally occurring amyloidosis remains unknown. (wikipedia.org)
  • studies
  • Lenalidomide and dexamethasone for AL amyloidosis have been evaluated in several phase II studies, with CR ranging from 29% to 42% by intention-to-treat analysis and a median time to response of six months. (haematologica.org)